BR Biopharma (NASDAQ:BRBI) Announces Quarterly Earnings Results

BR Biopharma (NASDAQ:BRBI) posted its quarterly earnings data on Thursday. The company reported $0.09 EPS for the quarter, FiscalAI reports. The business had revenue of $25.95 million during the quarter.

BR Biopharma Stock Performance

Shares of BRBI traded down $0.37 during trading hours on Friday, hitting $14.40. 797 shares of the stock were exchanged, compared to its average volume of 4,167. BR Biopharma has a 12-month low of $12.15 and a 12-month high of $67.01. The stock has a 50-day moving average price of $14.88.

Analyst Ratings Changes

Separately, Weiss Ratings started coverage on BR Biopharma in a research report on Friday, February 13th. They issued a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BR Biopharma has a consensus rating of “Sell”.

Institutional Investors Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC acquired a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th biggest holding.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.